Skip to main content
Clinical Trials/NCT00180323
NCT00180323
Completed
Not Applicable

ACC - Atrial Contribution to CRT

Boston Scientific Corporation1 site in 1 country43 target enrollmentNovember 2004

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Dilated Cardiomyopathy
Sponsor
Boston Scientific Corporation
Enrollment
43
Locations
1
Primary Endpoint
Optimal AV-Delay (AVD)
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This prospective study will evaluate in patients, fulfilling implant criteria for Cardiac Resynchronisation Therapy (CRT) implant, the optimal atrial contribution to the resynchronised ventricles in the event of right atrial pacing.

Detailed Description

All patients will undergo advanced echocardiographic examination pre-operative, pre-discharge after implantation and at 3 and 6-months follow-up. AV-delay optimization will be performed using aortic VTI measured by continuous wave Doppler in a modified 4-chamber view. During optimisation aortic VTI will be measured at different heart rates reached by increasing atrial pacing 10, 20 and 30 beats above intrinsic heart rate (IHR).

Registry
clinicaltrials.gov
Start Date
November 2004
End Date
December 2008
Last Updated
5 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Symptoms of heart failure
  • Left ventricular dysfunction
  • Ventricular dyssynchrony
  • 18 years or of legal age in order to give informed consent according to national laws
  • Able to understand the nature of the procedure
  • Available for follow-up on a regular basis at an approved investigational center

Exclusion Criteria

  • Atrial Fibrillation
  • Life expectancy of less than six months due to other medical conditions
  • For women: pregnancy or absence of medically accepted birth control
  • Inability or refusal to sign the Patient Informed Consent
  • Inability or refusal to comply with the follow up schedule or protocol requirements
  • Inability to undergo device implant, including general anaesthesia if required
  • Mechanical tricuspid prosthesis
  • Currently enrolled in another investigational study, including drug investigations
  • Hypertrophic Obstructive Cardiomyopathy (HOCM)
  • Not meeting the inclusion criteria

Outcomes

Primary Outcomes

Optimal AV-Delay (AVD)

Time Frame: Implant (baseline), 3 months and 6 months Follow-up

Optimal AV-Delay will be measured at implant (baseline ), 3months and 6 months Follow-up for intrinsic heart rate, and 10, 20 and 30 Bpm above intrinsic heart rate.

Aortic Velocity Time Integral (VTI)

Time Frame: At implant (baseline), 3 months and 6 months Follow-up

Velocity time integral of the aortic flow correlates with cardiac output and is an accepted parameter for optimization of Cardiac Resynchronization Therapy (CRT).

Secondary Outcomes

  • 6 Minute Walk Test(implant (baseline), 3 months and 6 months Follow-up)
  • Left Ventricular Ejection Fraction (LVEF)(implant (baseline), 3 Months, 6 Months)

Study Sites (1)

Loading locations...

Similar Trials